CXCR1 and breast cancer: This revealed a significant increased risk of early breast cancer event (recurrence or breast cancer-related death within 5 years of primary diagnosis) in the group of patients with tumours positive for PDGF-CC [Fig. 4b, HR 1.77 (95% confidence interval (CI) 1.03–3.04), P = 0.04].